Literature DB >> 12429515

Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes.

Karl Ljungberg1, Erik Rollman, Lars Eriksson, Jorma Hinkula, Britta Wahren.   

Abstract

In a multisubtype approach to HIV-1 vaccination, mice were immunized with HIV-1 envelope gp160 genes from subtypes A, B, and C. Subsequently the mice were challenged with syngeneic primary splenocytes infected with a HIV-1/MuLV pseudovirus carrying a subtype B genome. HIV-specific immune responses and protection were strongest in the group of animals immunized with a combination of subtype A, B, and C specific gp160 genes as compared to subtype B only. Immunization with the combination of the cross-reactive subtypes A and C envelope genes induced HIV-specific immune responses but did not result in significant protection to challenge with subtype B infected cells. From this we conclude that immunization with the envelope genes from several HIV-1 subtypes may indeed enhance immune responses. This study shows that by using a mix of subtype envelope genes, an enhanced protective immunity can be obtained experimentally, potentially also in humans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429515     DOI: 10.1006/viro.2002.1547

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

1.  Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.

Authors:  Eric Sandström; Charlotta Nilsson; Bo Hejdeman; Andreas Bråve; Göran Bratt; Merlin Robb; Josephine Cox; Thomas Vancott; Mary Marovich; Richard Stout; Said Aboud; Muhammad Bakari; Kisali Pallangyo; Karl Ljungberg; Bernard Moss; Patricia Earl; Nelson Michael; Deborah Birx; Fred Mhalu; Britta Wahren; Gunnel Biberfeld
Journal:  J Infect Dis       Date:  2008-11-15       Impact factor: 5.226

Review 2.  Polyvalent AIDS vaccines.

Authors:  Shan Lu; Jill M Grimes Serrano; Shixia Wang
Journal:  Curr HIV Res       Date:  2010-12       Impact factor: 1.581

3.  Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine.

Authors:  Sean P McBurney; Gary Landucci; Donald N Forthal; Ted M Ross
Journal:  AIDS Res Hum Retroviruses       Date:  2012-03-21       Impact factor: 2.205

4.  Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.

Authors:  Muhammad Bakari; Said Aboud; Charlotta Nilsson; Joel Francis; Deus Buma; Candida Moshiro; Eric A Aris; Eligius F Lyamuya; Mohamed Janabi; Karina Godoy-Ramirez; Agricola Joachim; Victoria R Polonis; Andreas Bråve; Patricia Earl; Merlin Robb; Mary Marovich; Britta Wahren; Kisali Pallangyo; Gunnel Biberfeld; Fred Mhalu; Eric Sandström
Journal:  Vaccine       Date:  2011-08-22       Impact factor: 3.641

Review 5.  Viral sequence diversity: challenges for AIDS vaccine designs.

Authors:  Sean P McBurney; Ted M Ross
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

6.  Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.

Authors:  Scott A Brown; Sherri L Surman; Robert Sealy; Bart G Jones; Karen S Slobod; Kristen Branum; Timothy D Lockey; Nanna Howlett; Pamela Freiden; Patricia Flynn; Julia L Hurwitz
Journal:  Viruses       Date:  2010-02-01       Impact factor: 5.048

7.  Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine.

Authors:  Karl Ljungberg; Alan C Whitmore; Meagan E Fluet; Timothy P Moran; Reed S Shabman; Martha L Collier; Annette A Kraus; Joseph M Thompson; David C Montefiori; Clayton Beard; Robert E Johnston
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

Review 8.  HIV-1 vaccine design: harnessing diverse lymphocytes to conquer a diverse pathogen.

Authors:  Sherri L Surman; Robert Sealy; Bart G Jones; Julia L Hurwitz
Journal:  Hum Vaccin       Date:  2009-04

Review 9.  Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine.

Authors:  Robert Sealy; Karen S Slobod; Patricia Flynn; Kristen Branum; Sherri Surman; Bart Jones; Pamela Freiden; Timothy Lockey; Nanna Howlett; Julia L Hurwitz
Journal:  Int Rev Immunol       Date:  2009       Impact factor: 5.311

10.  Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.

Authors:  Brian Burke; Victor Raúl Gómez-Román; Ying Lian; Yide Sun; Elaine Kan; Jeffrey Ulmer; Indresh K Srivastava; Susan W Barnett
Journal:  Virology       Date:  2009-02-27       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.